Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | IDE | P14735 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | HLCS | P50747 | 6/20 | 0.63 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838821 | 0.92 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8958855 | 0.92 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Iodide SCHEMBL2533594 | 0.91 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL425273 | 0.90 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5498960 | 0.90 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4464825 | 0.90 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8508662 | 0.90 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29375721 | 0.90 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2182339 | 0.90 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1936659 | 0.89 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107515-A1 | INCRETIN HORMONE COMPOSITIONS AND METHODS USING SAME | DIASOME PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG INC (US) | 2024-05-02 | — | — | US | claimed |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2024-04-04 | — | — | US | claimed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | claimed |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. (US) | 2023-06-08 | — | — | US | claimed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | claimed |
| EP-3952904-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| CN-101237854-A | Lipid construct for delivery of insulin to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | claimed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| EP-1883395-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006127360-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060228325-A1 | Water soluble multi-biotin-containing compounds | WILBUR D S | 2006-10-12 | — | — | US | claimed |
| EP-1196199-A4 | WATER SOLUBLE MULTI-BIOTIN-CONTAINING COMPOUNDS | UNIV WASHINGTON (US) | 2002-06-19 | — | — | EP | claimed |
| EP-1196199-A2 | WATER SOLUBLE MULTI-BIOTIN-CONTAINING COMPOUNDS | University of Washington (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2000072802-A2 | WATER SOLUBLE MULTI-BIOTIN-CONTAINING COMPOUNDS | UNIVERSITY OF WASHINGTON (US) | 2000-12-07 | — | — | WO | claimed |
| WO-1995025172-A1 | RECOMBINANT ANTIBODY FRAGMENTS WHICH ARE SYNTHESIZED AND BIOTINYLATED IN E. COLI, THEIR USE IN IMMUNOASSAYS AND IMMUNOPURIFICATION TECHNIQUES | UNIVERSITE LOUIS PASTEUR (FR) | 1995-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | TDP1 4738/4885MEN1 1515/4885ABL1 2221/4885 |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | TDP1 4755/4885MEN1 2415/4885ABL1 4626/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | TDP1 4833/4885MEN1 2073/4885ABL1 4576/4885 |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | LIPA, NPC1L1, PLIN3 | TDP1 3561/4885MEN1 1725/4885ABL1 2117/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20060228325-A1 | Water soluble multi-biotin-containing compounds | BTD, HLCS, VNN1 | TDP1 2706/4885MEN1 3462/4885ABL1 4752/4885 |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | TDP1 4800/4885MEN1 561/4885ABL1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.